Project Grant K22CA313096
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $186K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Temple, TX 76502, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute awarded Mayo Clinic $565,423 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate individualized DNA junction-based liquid biopsies for monitoring glioblastoma and high-grade gliomas during and after treatment. The research addresses a clinical gap in glioma surveillance. Current magnetic resonance imaging monitoring using RANO 2.0 criteria lacks sensitivity and specificity for detecting early disease...
- The National Institute of Neurological Disorders and Stroke awarded Baylor College of Medicine $624,825 on March 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop computational methods for characterizing electrophysiological and genomic profiles of gliomas. The award funds research integrating multi-modal data to link molecular and electrophysiological states of glioma cells and clarify mechanisms of...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $130,035 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on September 2, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on the mechanism and therapeutic potential of macrophage-stem cell symbiotic interaction in glioblastoma. The project investigates how tumor-associated macrophages and glioblastoma stem cells interact within the...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc. $602,121 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, to develop and validate advanced radio-pathomic mapping techniques that predict pathological tumor characteristics in glioblastoma using standard clinical MRI. The research addresses non-enhancing tumor regions that extend beyond visible MRI enhancement and harbor resistant cells serving as recurrence reservoirs, regions...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded Yale University $488,162 on August 19, 2026, under the Cancer Biology Research program (CFDA 93.396) to catalog disease processes over the lifespan of glioma using the International Glioma Longitudinal Analysis (GLASS) Consortium dataset. The award funds analysis of tumor heterogeneity and its evolution in response to treatment across the GLASS database, which since 2014 has...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...